LHU Stock Overview
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
LeMaitre Vascular, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$59.50 |
| 52 Week High | US$64.50 |
| 52 Week Low | US$42.00 |
| Beta | 0.88 |
| 1 Month Change | -4.03% |
| 3 Month Change | 19.00% |
| 1 Year Change | 23.44% |
| 3 Year Change | 42.34% |
| 5 Year Change | 135.78% |
| Change since IPO | 103.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| LHU | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.0% | -0.4% |
| 1Y | 23.4% | -2.8% | 3.4% |
Return vs Industry: LHU exceeded the German Medical Equipment industry which returned -0.9% over the past year.
Return vs Market: LHU exceeded the German Market which returned 4.9% over the past year.
Price Volatility
| LHU volatility | |
|---|---|
| LHU Average Weekly Movement | 5.1% |
| Medical Equipment Industry Average Movement | 5.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: LHU has not had significant price volatility in the past 3 months.
Volatility Over Time: LHU's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 622 | George LeMaitre | https://www.lemaitre.com |
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries.
LeMaitre Vascular, Inc. Fundamentals Summary
| LHU fundamental statistics | |
|---|---|
| Market cap | €1.34b |
| Earnings (TTM) | €27.73m |
| Revenue (TTM) | €178.22m |
49.7x
P/E Ratio7.7x
P/S RatioIs LHU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LHU income statement (TTM) | |
|---|---|
| Revenue | US$193.48m |
| Cost of Revenue | US$66.44m |
| Gross Profit | US$127.05m |
| Other Expenses | US$96.94m |
| Earnings | US$30.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.35 |
| Gross Margin | 65.66% |
| Net Profit Margin | 15.56% |
| Debt/Equity Ratio | 0% |
How did LHU perform over the long term?
See historical performance and comparison